Beyond the initial cash injection, the agreement includes the issuance of pre-funded warrants for 1.26 million shares of Evommune stock. Hinova remains positioned for significant long-term upside, with potential milestone-based payments reaching $150 million for development and regulatory benchmarks, plus an additional $920 million tied to further commercial milestones and tiered royalty structures.

To bolster its capital reserves alongside this acquisition, Evommune finalized a private placement of approximately 5 million shares at $6.04 per share. Scheduled to close on November 6, this offering is projected to generate $30 million in gross proceeds to support the company’s expanded pipeline.